Senate committee advances nominees for CDC director and pandemic preparedness chief

A key Senate committee has voted to advance the nominations of two senior health officials to the full chamber for confirmation, moving the Trump administration a step closer to installing new leadership at two of the country's most consequential public health posts. Erica Schwartz has been nominated to lead the Centers for Disease Control and Prevention, while Sean Kaufman has been tapped for the top role overseeing the country's pandemic and disaster medical response.

The committee vote follows a series of confirmation hearings in which both nominees faced questions from senators on both sides of the aisle about their vision for the agencies and how they would balance political direction from the White House with the scientific independence that has traditionally shaped the CDC's public communications during outbreaks.

Schwartz would take over an agency that has spent recent years navigating both the lingering effects of the Covid-19 pandemic response and a broader debate over how much authority federal health agencies should hold relative to state and local health departments. Her confirmation would put her at the center of the government's response to ongoing public health challenges, including active disease outbreaks being monitored internationally.

Kaufman, nominated for the position overseeing the Administration for Strategic Preparedness and Response, would be responsible for coordinating the country's stockpiles of medical countermeasures, its response to public health emergencies, and its readiness for future pandemics. The role has taken on additional prominence following criticism of the speed and coordination of past emergency responses.

Both nominees are seen within the administration as aligned with a broader push to reshape federal health agencies, a priority associated with the current health secretary. Supporters argue that new leadership is needed to modernize agencies that critics say became bureaucratically bloated and slow to adapt during recent public health crises.

Critics of the nominations, including some public health researchers and former agency officials, have expressed concern that the confirmation process has focused more on political alignment than on the nominees' technical public health credentials, at a time when the CDC and its counterparts face significant workforce and budget pressures.

The committee vote does not guarantee confirmation by the full Senate, where floor scheduling and broader political negotiations could still affect the timeline. Nominations to lead health agencies have, in recent years, occasionally stalled for months even after clearing committee votes, particularly when nominees become entangled in unrelated legislative disputes.

Health policy analysts note that whoever ultimately leads the CDC will face immediate operational decisions, from staffing levels at regional offices to the agency's posture on responding to emerging outbreaks abroad that carry the potential to reach the United States. The pandemic preparedness office, meanwhile, oversees decisions about stockpiling vaccines, therapeutics and protective equipment that could prove consequential during any future public health emergency.

Both nominees, if confirmed, would inherit agencies still adjusting to leadership turnover and reorganization efforts undertaken over the past several years. Career staff at both agencies have said publicly, through professional associations, that stability and clear direction from confirmed leadership would help address ongoing morale and retention concerns.

The full Senate is expected to take up both nominations in the coming weeks, with confirmation votes likely to fall largely along party lines, consistent with the pattern for senior health nominations in recent Congresses.